FDA Approves Truqap plus Faslodex for Patients with Advanced HR-Positive Breast Cancer
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the U.S. for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN). Eligible patients will have progressed on at least one endocrine-based regimen in the metastatic setting or experienced recurrence on or within 12 months of completing adjuvant therapy.
Breast cancer is the most common cancer and one of the leading causes of cancer-related death worldwide. HR-positive breast cancer (expressing estrogen or progesterone receptors, or both), is the most common subtype, with more than 65% of tumors considered HR-positive and HER2-low or HER2-negative. More than two million patients were diagnosed with breast cancer in 2020, with nearly 685,000 deaths globally. In the US, more than 290,000 patients are expected to be diagnosed in 2023, with more than 43,000 deaths.
